Results 1 to 10 of about 3,535 (191)
British Journal of Clinical Pharmacology, 2015 Mirabegron is used for the treatment of symptoms associated with overactive bladder syndrome. It selectively stimulates the β3‐adrenoreceptor, which relaxes the detrusor muscle. This improves urine storage by distension of the bladder body.
Sebastiaan C. Goulooze +2 more
core +6 more sources
Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate [PDF]
Frontiers in Pharmacology, 2021 Introduction: Mirabegron is available for treatment of storage symptoms in overactive bladder, which may be improved by β3-adrenoceptor-induced bladder smooth muscle relaxation. In addition to storage symptoms, lower urinary tract symptoms in men include
Ru Huang +7 more
doaj +2 more sources
Tzu Chi Medical Journal, 2022 Medical treatment of overactive bladder (OAB) includes antimuscarinic agents, beta-3 adrenoceptor agonist (mirabegron), or combination with both drugs. Recently, a meta-analysis reported the integrated clinical trial data from 10 phase 2–4, double-blind,
Hann-Chorng Kuo
doaj +1 more source
Mirabegron-Induced Smooth Muscle Relaxation: Review of the Suggested Mechanisms [PDF]
المجلة العراقية للصيدلة, 2023 Background: Mirabegron operates through a distinct mechanism compared to antimuscarinic agents. Its activation of β3-adrenoceptors results in the relaxation of the bladder during the filling phase of micturition.
Rahma Almallah, Hani Almukhtar
doaj +1 more source
Effects of mirabegron on depression, anxiety, learning and memory in mice
Anais da Academia Brasileira de Ciências, 2021 Mirabegron is the first b3-adrenoceptor agonist to enter clinical practice and has been approved for the treatment of symptoms of OAB. The aim of this study is to investigate whether the mirabegron has an effect on depression, anxiety, learning, and ...
MEHMET H. TANYERI +6 more
doaj +1 more source
Safety and Efficacy of Propiverine Hydrochloride Versus Mirabegron in Treating storage Symptoms in Patients with Benign Prostatic hyperplasia [PDF]
Zagazig University Medical Journal, 2023 Background: Overactive bladder (OAB) is a syndrome characterized by the presence of urgency, with or without urinary incontinence usually with increased daytime or night-time frequency.
ibrahem elsayed +3 more
doaj +1 more source
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia, 2023 Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021.
Luisa Gracio Ferreira Sartori +6 more
doaj +1 more source
pharma-kritik, 2014 Mit Mirabegron wird erstmals ein adrenerger Beta-Agonist zur Behandlung bei hyperaktiver Blase angeboten. Wie andere für diese Indikation geeignete Medikamente bewirkt Mirabegron eine relativ bescheidene Verbesserung der Miktionsbeschwerden. Diesbezüglich dürfte das neue Medikament gegenüber Anticholinergika – z.B.
openaire +2 more sources
Mirabegron and Physical Exercise Is a Potential Strategical for BAT Activation in Obesity
Obesities, 2022 (1) Background: Obesity is a global epidemic issue that has increased greatly in recent decades. Although interventions such as nutritional approaches and the practice of physical exercise are potential therapies to combat obesity, in some cases they are
Gabriel Calheiros Antunes +3 more
doaj +1 more source
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors
Current Therapeutic Research, 2022 : Background: The β3-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder.
Benjamin M. Brucker, MD +3 more
doaj +1 more source